Monthly Archives: January 2018

Inflammation triggers stem cell proliferation to repair the tissue damage, while abnormal gene expression can transform temporary hyperplasia into a fertile ground for tumorigenesis. We investigated the role and mechanism of microRNA miR-34a deficiency… Continue reading →

The generation of high-quality pilot data that leads to “go/no-go decisions” regarding new or repurposed drugs is often problematic, particularly with a high placebo response rate. In short duration trials, pharmacodynamic (PD) biomarkers can demon… Continue reading →

Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection. To provide effective FMT protocol for ulcerative colitis (UC) has been desired. We previously reported that the combination therapy with mul… Continue reading →

A comorbidity of inflammatory bowel disease (IBD) is inflammation-induced bone loss characterized by elevated bone resorption and decreased bone formation. Fracture incidence is resultantly elevated. Using a TNBS rat model, we have found osteocytes, ce… Continue reading →

Existing data regarding the association between inflammatory bowel disease (IBD) and pregnancy outcomes is lacking in Korea. Continue reading →

Exercise has been shown to be safe and have symptom reduction in patients with inflammatory bowel disease (IBD). However, there has been inconsistent incorporation of physical activity in IBD management. This study evaluated physician awareness of exer… Continue reading →

Crohn’s Disease and ulcerative colitis present distinct characteristics, one being the expansion of mesenteric adipose tissue (MAT) surrounding the inflamed intestinal tract (“creeping fat”-CF), which is typical for CD and absent in UC. To-date, … Continue reading →

Patients with ulcerative colitis (UC) who have experienced failure of TNF antagonist (aTNF) therapy are a difficult-to-treat population with a notable unmet medical need. Centrally read endoscopy demonstrates reduced placebo remission rates as low as 0… Continue reading →

The AGA, RMEI (CME company), and RealCME (technology company), designed and implemented a phased CME continuum in IBD, directed at 17,000 AGA members and a national sample of GI clinicians. The design was driven by the recognition of shortcomings in pr… Continue reading →

TGF-β1 is a central pro-fibrotic cytokine in stricturing Crohn’s disease. Its affects are normally inhibited by increased Smad7 expression. We have shown that Smad7 is silenced in stricturing Crohn’s disease by TGF-β1 activated, Smad3-dependent e… Continue reading →